DOI 10.1007/s00296-011-2033-5ORIGINAL ARTICLE

Arnaud Roucheux
Ingrid Dedreux
Serge Jacquot
Xavier Le Loët
Olivier Boyer
Olivier Vittecoq

October 2016

Original article doi:10.1093/rheumatology/ker183 Number and phenotype of rheumatoid arthritis patien...

Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study.

Burmester, Gerd
Matucci-Cerinic, Marco
Mariette, Xavier
Navarro-Blasco, Francisco
Kary, Sonja
Unnebrink, Kristina
Kupper, Hartmut

January 2014

International audienceINTRODUCTION: Patients with active rheumatoid arthritis who had failed at leas...

Adalimumab alone and in combination with disease- modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: The Research in Active Rheumatoid Arthritis (ReAct) trial.

BURMESTER GR
MARIETTE X
MONTEAGUDO SAEZ I
MALAISE M
TZIOUFAS AG
BIJLSMA JW
UNNEBRINK K
KARY S
KUPPER H.
MONTECUCCO, CARLOMAURIZIO

January 2007

Objective: To evaluate the safety and effectiveness of adalimumab alone or in combination with stand...

Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational study

Kleinert, Stefan
Tony, Hans-Peter
Krause, Andreas
Feuchtenberger, Martin
Wassenberg, Siegfried
Richter, Constanze
Räther, Ekkehard
Spieler, Wolfgang
Gnann, Holger
Wittig, Bianca M.

January 2012

The objective of this study was to use data from a noninterventional study to evaluate the effective...

Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German

Kleinert, Stefan
Tony, Hans-Peter
Krause, Andreas
Feuchtenberger, Martin
Wassenberg, Siegfried
Richter, Constanze
Röther, Ekkehard
Spieler, Wolfgang
Gnann, Holger
Wittig, Bianca M.

January 2012

The objective of this study was to use data from a noninterventional study to evaluate the effective...

The impact of prior biologic therapy on adalimumab response in patients with rheumatoid arthritis.

Feuchtenberger, M.
Kleinert, S.
Scharbatke, E.C.
Gnann, H.
Behrends, F.
Wittig, B.M.
Greger, G.
Tony, H.P.

January 2015

OBJECTIVES: The aim of this study is to use data from a non-interventional study of adalimumab in pa...

Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability

Iannone, Florenzo
Sinigaglia, Lugi
Favalli, Ennio Giulio
Sarzi Puttini, Piercarlo
Atzeni, Fabiola
Caporali, Roberto
Codullo, Veronica
Ferraccioli, Gianfranco
Gremese, Elisa
Carletto, Antonio
Giollo, Alessandro
Govoni, Marcello
Bergossi, Francesca
Galeazzi, Mauro
Cantarini, Luca
Salaffi, Fausto
Di Carlo, Marco
Bazzani, Chiara
Pellerito, Raffaele
Sebastiani, Marco
Ramonda, Roberta
Lapadula, Giovanni

January 2016

The purpose of the study was to estimate the clinical profile of naïve biological patients with rheu...

Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability

Iannone, Florenzo
Sinigaglia, Lugi
Favalli, Ennio Giulio
Sarzi Puttini, Piercarlo
Atzeni, Fabiola
Caporali, Roberto
Codullo, Veronica
Ferraccioli, Gianfranco
Gremese, Elisa
Carletto, Antonio
Giollo, Alessandro
Govoni, Marcello
Bergossi, Francesca
Salaffi, Fausto
Di Carlo, Marco
Bazzani, Chiara
Pellerito, Raffaele
Sebastiani, Marco
Ramonda, Roberta
Lapadula, Giovanni
GALEAZZI, MAURO
CANTARINI, LUCA

January 2016

The purpose of the study was to estimate the clinical profile of naïve biological patients with rheu...

Adalimumab effect in a cohort of Libyan patients with rheumatic diseases

Basma, E
Rajab, T
Manal, E

July 2017

Background: Adalimumab is a recombinant human IgG1 monoclonal antibody. It is a tumour necrosis fact...

Är adalimumab en bra behandling mot reumatoid artrit i jämförelse med andra biologiska läkemedel?

Yasin, Salim Awell

January 2021

Rheumatoid arthritis (RA) is an autoimmune disease, which causes joint inflammation. Different envir...

Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings : high rate remission together with normal function ability

F. Iannone
L. Sinigaglia
E.G. Favalli
P. Sarzi-Puttini
F. Atzeni
R. Caporali
V. Codullo
G. Ferraccioli
E. Gremese
A. Carletto
A. Giollo
M. Govoni
F. Bergossi
M. Galeazzi
L. Cantarini
F. Salaffi
M. Di Carlo
C. Bazzani
R. Pellerito
M. Sebastiani
R. Ramonda
G. Lapadula

November 2016

The purpose of the study was to estimate the clinical profile of na\uefve biological patients with r...

Association of Improvement in Pain with Therapeutic Response as Determined by Individual Improvement Criteria in Patients with Rheumatoid Arthritis

Scharbatke, E.C.
Behrens, F.
Schmalzing, M.
Koehm, M.
Greger, G.
Gnann, H.
Burkhardt, H.
Tony, H.-P.

January 2016

Objective To use statistical methods to establish a threshold for individual response in patient-rep...

Impact of participation in the Adalimumab (Humira) patient support program on rheumatoid arthritis treatment course : results from the PASSION study

Van den Bosch, Filip
Ostor, Andrew JK
Wassenberg, Siegfried
Chen, Naijun
Wang, Chen
Garg, Vishvas
Kalabic, Jasmina

January 2017

Introduction: Patients with rheumatoid arthritis (RA) who are treated with adalimumab (ADA) are offe...

Disease activity in rheumatoid arthritis patients at initiation of biologic agents and 1 year of treatment: results from the Swiss SCQM registry.

Zufferey, P.
Dudler, J.
Scherer, A.
Finckh, A.

January 2013

OBJECTIVE: In Switzerland, the prescription of biologic antirheumatic agents in rheumatoid arthritis...

RESEARCH ARTICLE Safety and effectiveness o d n

Trial Registration Nct

August 2016

Full list of author information is available at the end of the articleIntroduction Patients with rhe...

not affected by adalimumab

Arnaud Roucheux
Ingrid Dedreux
Serge Jacquot
Xavier Le Loët
Olivier Boyer
Olivier Vittecoq

October 2016

Original article doi:10.1093/rheumatology/ker183 Number and phenotype of rheumatoid arthritis patien...

Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study.

Burmester, Gerd
Matucci-Cerinic, Marco
Mariette, Xavier
Navarro-Blasco, Francisco
Kary, Sonja
Unnebrink, Kristina
Kupper, Hartmut

January 2014

International audienceINTRODUCTION: Patients with active rheumatoid arthritis who had failed at leas...

Adalimumab alone and in combination with disease- modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: The Research in Active Rheumatoid Arthritis (ReAct) trial.

BURMESTER GR
MARIETTE X
MONTEAGUDO SAEZ I
MALAISE M
TZIOUFAS AG
BIJLSMA JW
UNNEBRINK K
KARY S
KUPPER H.
MONTECUCCO, CARLOMAURIZIO

January 2007

Objective: To evaluate the safety and effectiveness of adalimumab alone or in combination with stand...

Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational study

Kleinert, Stefan
Tony, Hans-Peter
Krause, Andreas
Feuchtenberger, Martin
Wassenberg, Siegfried
Richter, Constanze
Räther, Ekkehard
Spieler, Wolfgang
Gnann, Holger
Wittig, Bianca M.

January 2012

The objective of this study was to use data from a noninterventional study to evaluate the effective...

Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German

Kleinert, Stefan
Tony, Hans-Peter
Krause, Andreas
Feuchtenberger, Martin
Wassenberg, Siegfried
Richter, Constanze
Röther, Ekkehard
Spieler, Wolfgang
Gnann, Holger
Wittig, Bianca M.

January 2012

The objective of this study was to use data from a noninterventional study to evaluate the effective...

The impact of prior biologic therapy on adalimumab response in patients with rheumatoid arthritis.

Feuchtenberger, M.
Kleinert, S.
Scharbatke, E.C.
Gnann, H.
Behrends, F.
Wittig, B.M.
Greger, G.
Tony, H.P.

January 2015

OBJECTIVES: The aim of this study is to use data from a non-interventional study of adalimumab in pa...

Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability

Iannone, Florenzo
Sinigaglia, Lugi
Favalli, Ennio Giulio
Sarzi Puttini, Piercarlo
Atzeni, Fabiola
Caporali, Roberto
Codullo, Veronica
Ferraccioli, Gianfranco
Gremese, Elisa
Carletto, Antonio
Giollo, Alessandro
Govoni, Marcello
Bergossi, Francesca
Galeazzi, Mauro
Cantarini, Luca
Salaffi, Fausto
Di Carlo, Marco
Bazzani, Chiara
Pellerito, Raffaele
Sebastiani, Marco
Ramonda, Roberta
Lapadula, Giovanni

January 2016

The purpose of the study was to estimate the clinical profile of naïve biological patients with rheu...

Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability

Iannone, Florenzo
Sinigaglia, Lugi
Favalli, Ennio Giulio
Sarzi Puttini, Piercarlo
Atzeni, Fabiola
Caporali, Roberto
Codullo, Veronica
Ferraccioli, Gianfranco
Gremese, Elisa
Carletto, Antonio
Giollo, Alessandro
Govoni, Marcello
Bergossi, Francesca
Salaffi, Fausto
Di Carlo, Marco
Bazzani, Chiara
Pellerito, Raffaele
Sebastiani, Marco
Ramonda, Roberta
Lapadula, Giovanni
GALEAZZI, MAURO
CANTARINI, LUCA

January 2016

The purpose of the study was to estimate the clinical profile of naïve biological patients with rheu...

Adalimumab effect in a cohort of Libyan patients with rheumatic diseases

Basma, E
Rajab, T
Manal, E

July 2017

Background: Adalimumab is a recombinant human IgG1 monoclonal antibody. It is a tumour necrosis fact...

Är adalimumab en bra behandling mot reumatoid artrit i jämförelse med andra biologiska läkemedel?

Yasin, Salim Awell

January 2021

Rheumatoid arthritis (RA) is an autoimmune disease, which causes joint inflammation. Different envir...

Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings : high rate remission together with normal function ability

F. Iannone
L. Sinigaglia
E.G. Favalli
P. Sarzi-Puttini
F. Atzeni
R. Caporali
V. Codullo
G. Ferraccioli
E. Gremese
A. Carletto
A. Giollo
M. Govoni
F. Bergossi
M. Galeazzi
L. Cantarini
F. Salaffi
M. Di Carlo
C. Bazzani
R. Pellerito
M. Sebastiani
R. Ramonda
G. Lapadula

November 2016

The purpose of the study was to estimate the clinical profile of na\uefve biological patients with r...

Association of Improvement in Pain with Therapeutic Response as Determined by Individual Improvement Criteria in Patients with Rheumatoid Arthritis

Scharbatke, E.C.
Behrens, F.
Schmalzing, M.
Koehm, M.
Greger, G.
Gnann, H.
Burkhardt, H.
Tony, H.-P.

January 2016

Objective To use statistical methods to establish a threshold for individual response in patient-rep...

Impact of participation in the Adalimumab (Humira) patient support program on rheumatoid arthritis treatment course : results from the PASSION study

Van den Bosch, Filip
Ostor, Andrew JK
Wassenberg, Siegfried
Chen, Naijun
Wang, Chen
Garg, Vishvas
Kalabic, Jasmina

January 2017

Introduction: Patients with rheumatoid arthritis (RA) who are treated with adalimumab (ADA) are offe...

Disease activity in rheumatoid arthritis patients at initiation of biologic agents and 1 year of treatment: results from the Swiss SCQM registry.

Zufferey, P.
Dudler, J.
Scherer, A.
Finckh, A.

January 2013

OBJECTIVE: In Switzerland, the prescription of biologic antirheumatic agents in rheumatoid arthritis...

RESEARCH ARTICLE Safety and effectiveness o d n

Trial Registration Nct

August 2016

Full list of author information is available at the end of the articleIntroduction Patients with rhe...

not affected by adalimumab

Arnaud Roucheux
Ingrid Dedreux
Serge Jacquot
Xavier Le Loët
Olivier Boyer
Olivier Vittecoq

October 2016

Original article doi:10.1093/rheumatology/ker183 Number and phenotype of rheumatoid arthritis patien...

Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study.

Burmester, Gerd
Matucci-Cerinic, Marco
Mariette, Xavier
Navarro-Blasco, Francisco
Kary, Sonja
Unnebrink, Kristina
Kupper, Hartmut

January 2014

International audienceINTRODUCTION: Patients with active rheumatoid arthritis who had failed at leas...

Adalimumab alone and in combination with disease- modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: The Research in Active Rheumatoid Arthritis (ReAct) trial.

BURMESTER GR
MARIETTE X
MONTEAGUDO SAEZ I
MALAISE M
TZIOUFAS AG
BIJLSMA JW
UNNEBRINK K
KARY S
KUPPER H.
MONTECUCCO, CARLOMAURIZIO

January 2007

Objective: To evaluate the safety and effectiveness of adalimumab alone or in combination with stand...

DOI 10.1007/s00296-011-2033-5ORIGINAL ARTICLE

Abstract

Extracted data

DOI 10.1007/s00296-011-2033-5ORIGINAL ARTICLE

Abstract

Extracted data

Related items

Related items